Sunitinib+Docetaxel Not Recommended for First-Line Treatment of HER2/neu Advanced Breast Cancer

Share this content:

(ChemotherapyAdvisor) – The combination of sunitinib plus docetaxel improved the objective response rate (ORR) but did not prolong progression-free survival (PFS) or overall survival (OS) vs. docetaxel alone for the first-line treatment of HER2/neu–negative advanced breast cancer, a Phase 3 randomized study concluded in the Journal of Clinical Oncology online February 13.

The study randomly assigned patients to sunitinib 37.5mg/day (days 2–15) plus docetaxel 75mg/m2 (day 1) every 3 weeks (n=296) or docetaxel 100mg/m2 alone every 3 weeks (n=297).

The ORR was 55% for the sunitinib plus docetaxel vs. 42% for docetaxel alone; however, PFS, the primary end point, was not met: median PFS was 8.6 months for sunitinib plus docetaxel vs. 8.3 months for docetaxel alone. Response duration was 7.5 months for the combination vs. 7.2 months for monotherapy; median OS was 24.8 and 25.5 months, respectively.

In the sunitinib plus docetaxel arm, there were 107 deaths and, in the docetaxel alone arm, 91 deaths. Patients receiving the combination regimen had more adverse events (AEs) — specifically, a 16% increase in grade 3 to 4 hand-foot syndrome compared with monotherapy — and a higher number of treatment discontinuations due to AEs.

“The sunitinib-docetaxel regimen evaluated in this study is not recommended for further use in advanced breast cancer,” the authors wrote.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs